
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced encouraging topline results from preclinical studies evaluating tivoxavir marboxil (TXM) as a potential treatment for H5N1 bird flu. The investigational oral therapy, …
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment Read More